DrugPatentWatch Database Preview
Pharmacyclics Inc Company Profile
What is the competitive landscape for PHARMACYCLICS INC, and when can generic versions of PHARMACYCLICS INC drugs launch?
PHARMACYCLICS INC has two approved drugs.
There are thirty-two US patents protecting PHARMACYCLICS INC drugs.
There are two hundred and forty-five patent family members on PHARMACYCLICS INC drugs in thirty-nine countries and twenty-six supplementary protection certificates in eleven countries.
Summary for Pharmacyclics Inc
| International Patents: | 245 |
| US Patents: | 32 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Pharmacyclics Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-004 | Feb 16, 2018 | RX | Yes | Yes | 8,497,277 | Start Trial | Start Trial | ||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | 8,754,091 | Start Trial | Y | Start Trial | |||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | 8,703,780 | Start Trial | Start Trial | ||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-003 | Feb 16, 2018 | RX | Yes | No | 10,125,140 | Start Trial | Y | Y | Start Trial | ||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-002 | Feb 16, 2018 | RX | Yes | No | 10,213,386 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for PHARMACYCLICS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 140 mg and 560 mg | ➤ Subscribe | 2018-11-05 |
| ➤ Subscribe | Capsules | 70 mg | ➤ Subscribe | 2018-12-14 |
| ➤ Subscribe | Tablets | 280 mg and 420 mg | ➤ Subscribe | 2018-12-14 |
International Patents for Pharmacyclics Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 201492082 | Start Trial |
| Taiwan | 201811334 | Start Trial |
| Israel | 239154 | Start Trial |
| Lithuania | PA2017009 | Start Trial |
| Brazil | PI0622054 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pharmacyclics Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2201840 | 2015/020 | Ireland | Start Trial | PRODUCT NAME: IBRUTINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/945 20141021 |
| 2201840 | 300728 | Netherlands | Start Trial | DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), SAMENVOEGEN |
| 2201840 | 92692 | Luxembourg | Start Trial | PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20141023 |
| 2201840 | CR 2015 00021 | Denmark | Start Trial | PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141023 |
| 2201840 | CA 2015 00021 | Denmark | Start Trial | PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141021 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
